Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44])
The summary for the Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), invites Small Business Innovation Research (SBIR) cooperative agreement applications from small business concerns (SBCs) that propose to develop new, or to improve existing application(s) of nanotechnology-based therapeutics or/and in vivo diagnostics. This FOA will specifically support pre-clinical optimization and testing of these cancer-relevant nanotechnology applications against the intended cancer type. The proposed projects must be milestone-driven and must be clearly directed toward development of an ultimate commercial product. The outcomes are expected to advance the discovery and pre-clinical optimization phase so that an Investigational New Drug (IND) or Investigational Device Exemptions (IDE) application could be submitted to the Food and Drug Administration (FDA) by the end or shortly after completion of the Phase II project period. To facilitate these steps, the NCI will assist the awardees in various ways, including the support through the NCI-sponsored Nanotechnology Characterization Laboratory. This FOA will NOT support basic research projects, studies on disease mechanisms, and clinical trials. Mechanism of Support. This FOA will utilize the SBIR (U43/U44) cooperative agreement mechanisms for Phase I and Phase II applications. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
Federal Grant Title: | Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) |
Federal Agency Name: | National Institutes of Health |
Grant Categories: | Education Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-10-286 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.393 |
CFDA Descriptions: | Cancer Cause and Prevention Research |
Current Application Deadline: | Jul 08, 2013 |
Original Application Deadline: | Jul 08, 2013 |
Posted Date: | Sep 21, 2010 |
Creation Date: | Sep 21, 2010 |
Archive Date: | Aug 08, 2013 |
Total Program Funding: | |
Maximum Federal Grant Award: | $150,000 |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]] - Similar Government Grants
- • Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
- • Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- • National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer ...
- • Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Cli...
- • Early-Stage Development of Informatics Technologies for Cancer Research and Management (U0...
- • Pilot Studies in Pancreatic Cancer
- • Cancer Prevention Research Small Grant Program
- • Molecular Targets for Nutrients in Prostate Cancer Prevention
- More Grants from the National Institutes of Health
- • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- • Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
- • Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clin...
- • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
- • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...